Why the study?
Does rivaroxaban prevent stroke in elderly polymorbid patients with non-valvular atrial fibrillation compared to warfarin?
Does rivaroxaban prevent stroke in elderly polymorbid patients with non-valvular atrial fibrillation compared to warfarin?
This review discusses the efficacy and safety of rivaroxaban for stroke prevention in elderly patients with non-valvular atrial fibrillation, based on ROCKET-AF and real-world data.
May support rivaroxaban in elderly non-valvular AF; leaves open optimal use in polymorbid patients.
Data regarding efficacy and safety of direct oral anticoagulant rivaroxaban in prevention of stroke in elderly polymorbid patients with non-valvular atrial fibrillation are presented. In this aspect results of randomized clinical trial in direct comparison of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation ROCKET-AF are discussed. Results of rivaroxaban use in elderly patients in real medical practice are also considered.
No takes yet. Share an insight, caveat, or question.
I. S. Yavelov (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: